Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02673138 · ClinicalTrials.gov registry record · NA

Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion

A NA study of Type 1 Diabetes, sponsored by Yale University.

Completed
Registry status
NA
Development phase
10
Enrollment target
1
Study location

NCT02673138 is a NA study of Type 1 Diabetes that has completed, run by Yale University. The registered enrollment target is 10 participants, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02673138, a NA study of Type 1 Diabetes, has completed, sponsored by Yale University.

COMPLETED
Registry status
NA
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

This study will be an open-label, cross-over study as subjects will be studied under both study conditions - suspension of subcutaneous insulin infusion via pump during treatment with insulin alone (control) vs. suspension of subcutaneous insulin via pump during treatment with insulin and canagliflozin.

Conditions Studied

Type 1 Diabetes

Interventions

  • DRUG canagliflozin
  • OTHER basal interruption without canagliflozin

Study Locations (1)

Connecticut

  • Yale University School of Medicine - New Haven

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2016-01
Est. Completion 2017-07
Phase NA

Sponsor

Yale University

1,492 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02673138

The ClinicalTrials.gov registry entry for NCT02673138 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (99% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which canagliflozin is the first listed.

NCT02673138 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT02673138 about?

NCT02673138 is a clinical study titled "Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion". This study will be an open-label, cross-over study as subjects will be studied under both study conditions - suspension of subcutaneous insulin infusion via pump during treatment with insulin alone (control) vs. suspension of subcutaneous insulin via pump during treatment with insulin and canagliflo...

What is the current status of trial NCT02673138?

This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2016-01. Estimated completion is 2017-07.

What conditions does trial NCT02673138 study?

This clinical trial studies the following conditions: Type 1 Diabetes.

What interventions are being tested in trial NCT02673138?

The interventions under investigation include: canagliflozin (DRUG), basal interruption without canagliflozin (OTHER).

Who is sponsoring clinical trial NCT02673138?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02673138 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 1 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 1 Diabetes

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.